A Phase 4 interventional study of Ferrous Sulfate Oral Product in Cerebral Palsy and Iron Deficiency Anemia, sponsored by Shaheed Zulfiqar Ali Bhutto Medical University. Not yet recruiting. Open to participants aged 6 Months to 60 Months. Per ClinicalTrials.gov, last updated 2024-01-17.
Sponsored by Shaheed Zulfiqar Ali Bhutto Medical University · Phase 4, Interventional, and Treatment
a randomized clinical trial to compare the effect of twice weekly versus daily iron therapy in treating anemia in children with cerebral palsy, to be conducted at Department of pediatric medicine children's hospital PIMS islamabad.
a total of 160 children of either gender with age between 6 and 60 months diagnosed with cerebral palsy and concomitant iron deficiency anemia will be enrolled, they will be allocated two groups by lottery method. one group will be given ferrous sulphate 3mg/kg daily in the form of syrup and other group will be given ferrous sulphate 3mg/kg twice weekly in the form of syrup for a period of 4 weeks. the primary outcome will be measured as rise in hemoglobin levels more than or equal to 1g/dl at 4 weeks.
1,936 studies on the registry are indexed under Cerebral Palsy; 458 are open to participants now.
This study's planned enrollment of 160 is above the median of 34 across 1,431 interventional studies indexed under Cerebral Palsy.
Browse Cerebral Palsy studies →Shaheed Zulfiqar Ali Bhutto Medical University is the lead sponsor of 37 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
one group will receive ferrous sulphate 3mg/kg in the form of syrup daily
Drug: Ferrous Sulfate Oral Product
other group will receive ferrous sulphate 3mg/kg in the form of syrup twice weekly.
Drug: Ferrous Sulfate Oral Product
ferrous sulphate oral in the form of syrup
Change in Hemoglobin levels from baseline
rise in Hb at the end of 4 weeks as more than equal to 1g/dl
Time frame: 4 weeks
Mean change in MCV (Mean Corpuscular Volume)
mean change from baseline at the end of 4 weeks
Time frame: 4 weeks
Mean change in mean corpuscular hemoglobin concentration (MCHC)
mean change from baseline at the end of 4 weeks
Time frame: 4 weeks
No study locations are listed for this record.
This study is not yet recruiting, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferrous sulfate
Shaheed Zulfiqar Ali Bhutto Medical University